



Dr.
Address
Institution

Country

Order no.:

Order received: DD-MM-YYYY

Sample type / Sample collection date:

blood, CentoCard® / DD-MM-YYYY

Report date: DD-MM-YYYY

Report type: Final Report

Patient no.: First Name:, Last Name:

DOB: DD-MM-YYYY, Sex: male, Your ref.:

Test(s) requested: CentoGenome® MOx 2.0 Solo

CLINICAL INFORMATION

Abnormal facial shape; Accessory spleen; Agitation; Antenatal onset; Autistic behavior; Delayed speech and language development; Global developmental delay; Hyperopic astigmatism; Hypertonia; Hypotropia; Intrauterine growth retardation; Low frustration tolerance; Motor delay; Paroxysmal drowsiness; Repetitive compulsive behavior; Stereotypical body rocking; Strabismus

(Clinical information indicated above follows HPO nomenclature.)

Diagnosed condition(s): hypertrophic syndrome.

Family history: Unknown.

Consanguineous parents: No.



POSITIVE RESULT

Likely pathogenic variant identified

INTERPRETATION

A hemizygous likely pathogenic was identified in the *KDM5C* gene. A splicing impact was observed by mRNA sequencing. **The result is consistent with the genetic diagnosis of Claes-Jensen type of X-linked syndromic intellectual developmental disorder.**

No further clinically relevant variants related to the described phenotype were detected.

RECOMMENDATIONS

- If possible, maternal targeted testing is recommended to establish whether the detected variant is inherited or *de novo*. If inherited, targeted testing for all affected, if any, and at-risk family members is recommended.
- Genetic counselling, including reproductive counselling (discussing prenatal and preimplantation diagnoses, if relevant), is recommended.

> Contact Details

Tel.: +49 (0)381 80113 416

Fax: +49 (0)381 80113 401

customer.support@centogene.com

www.centogene.com

CLIA registration 99D2049715; CAP registration 8005167. Scientific use of these results requires permission of CEN TOGENE. If you would like to download your reports from our web portal, please contact us to receive your login and password. More information is available at www.centogene.com or customer.support@centogene.com.





MAIN FINDINGS

SEQUENCE VARIANTS							
GENE	VARIANT COORDINATES	AMINO ACID CHANGE	SNP IDENTIFIER	ZYGOSITY	IN SILICO PARAMETERS*	ALLELE FREQUENCIES**	TYPE AND CLASSIFICATION***
<i>KDM5C</i>	NM_004187.3:c.2243+5G>A	p.?	N/A	hemizygous	PolyPhen: - SIFT: N/A MutationTaster: N/A Conservation_nt: N/A	gnomAD: - ESP: - 1000 G: -	Splice effect likely pathogenic

Variant annotation based on CentoCloud Bioinformatics pipeline. * Splicing predictions: Ada and RF scores. ** Genome Aggregation Database (gnomAD), Exome Sequencing Project (ESP), 1000Genome project (1000G). *** Based on ACMG recommendations.

VARIANT INTERPRETATION

KDM5C, c.2243+5G>A p.?

The *KDM5C* variant c.2243+5G>A is predicted to disrupt the highly conserved donor splice site. A splicing impact was observed by mRNA sequencing with the skipping of exon 15 (15 out of 26, NM_004187.3), r.2063_2243del. It is classified as likely pathogenic according to the recommendations of CENTOGENE and ACMG (please, see additional information below).

Syndromic X-linked intellectual disability Claes-Jensen type is characterized by mild to severe intellectual deficit associated with variable clinical manifestations including spasticity, cryptorchidism, maxillary hypoplasia, alopecia areata, epilepsy, short stature, impaired speech and behavioural problems. To date, it has been described in less than 15 families.

Mode of Inheritance: X-linked recessive (OMIM®: 300534)

METHODS

CentoGenome® MOx 2.0 Solo

Genomic DNA is enzymatically fragmented and tagged with Illumina compatible adapter sequences. The libraries are paired-end sequenced on an Illumina platform to yield an average coverage depth of ~ 30x. A bioinformatics pipeline based on the DRAGEN pipeline from Illumina, as well as CENTOGENE's in-house pipeline is applied. The sequencing reads are aligned to the Genome Reference Consortium Human Build 37 (GRCh37/hg19), as well as the revised Cambridge Reference Sequence (rCRS) of the Human Mitochondrial DNA (NC_012920). Sequence variants (SNVs/indels) and copy number variants (CNVs) are called using DRAGEN, Manta and in-house algorithms. Variants with a minor allele frequency (MAF) of less than 1% in gnomAD database, or disease-causing variants reported in HGMD®, in ClinVar or in CENTOGENE's in-house Biodatabank are evaluated. Although the evaluation is focused on coding exons and flanking intronic regions, the complete gene is interrogated for candidate variants with plausible association to the phenotype. All potential modes of inheritance are considered. In addition, the provided clinical information and family history are used to evaluate identified variants with respect to their pathogenicity and disease causality. Sequence variants are categorized into five classes (pathogenic, likely pathogenic, variant of uncertain significance [VUS], likely benign, and benign) according to ACMG/AMP guidelines for classification of variants in addition to ClinGen recommendations. CNVs are categorized into five classes (pathogenic, likely pathogenic, variant of uncertain significance [VUS], likely benign, and benign) according to ACMG/ClinGen guidelines for classification of CNVs. Additionally, other types of clinically relevant variants can be identified (e.g. risk factors, modifiers). All relevant variants related to the phenotype of the patient are reported. Likely benign and benign variants are not reported. CNVs of unknown significance with no apparent relation to the patient's phenotype are not reported. Mitochondrial variants with a heteroplasmy level of 15% or higher are reported. For detection of SNVs and indels in the regions targeted for downstream analysis a sensitivity of 99.9%, a specificity of 99.9%, and an accuracy of 99.9% is achieved. CNV detection software has a sensitivity of more than 95%. CENTOGENE has established stringent quality criteria and validation processes for variants detected by NGS. Reportable variants detected by NGS that do not reach internal quality and validation standards (including but not limited to, variants with unclear zygosity including mosaic calls, CNVs encompassing complex genomic regions, CNVs below 500kb) are confirmed by orthogonal methods. CNVs involving clinically significant imprinted regions are further investigated by MS-MLPA analysis. Consequently, a specificity of > 99.9% for all reported variants is warranted. Screening of repeat expansions is performed by the ExpansionHunter algorithm for the following genes: *AR*, *ATN1*, *ATXN1*, *ATXN2*, *ATXN3*, *ATXN7*, *ATXN8OS*, *ATXN10*, *CACNA1A*, *CNBP*, *CSTB*, *C9orf72*, *DMPK*, *FMR1*, *FXN*, *HTT*, *JPH3*, *NOP56*, *PABPN1*, *PHOX2B*, *PPP2R2B*, *PRNP* and *TBP*. The technical results of repeat expansion screenings will be correlated with the clinical information provided. Any repeat expansion called and considered relevant to the phenotype will be confirmed by an orthogonal method. *GBA1* screening is performed using Gaussian algorithm to detect recombination events affecting the region encompassing exons 9-11 (NM_000157.3), a region which has the highest homology to *GBAP1*. Any detected recombination event is reported only when considered relevant to the phenotype. Spinal muscular atrophy (SMA) screening is performed using SMN Caller algorithm to detect the copy number of the *SMN1* gene. Screening of uniparental isodisomy (isoUPD) is performed using an in-house algorithm for Mendelian inheritance errors (MIE) to detect runs of homozygosity (ROH) for the well-known clinically relevant chromosomal regions (6q24, 7, 11p15.5, 14q32, 15q11q13, 20q13 and 20).

> Contact Details

Tel.: +49 (0)381 80113 416
Fax: +49 (0)381 80113 401
customer.support@centogene.com
www.centogene.com

CLIA registration 99D2049715; CAP registration 8005167. Scientific use of these results requires permission of CENTOGENE. If you would like to download your reports from our web portal, please contact us to receive your login and password. More information is available at www.centogene.com or customer.support@centogene.com.





RNA is isolated from CentoCard®. Encoding messenger RNA (mRNA) is enriched, fragmented, and transcribed into complementary DNA (cDNA), followed by adapter ligation and amplification of the stranded libraries. The libraries are paired-end sequenced on an Illumina platform. An in-house bioinformatics pipeline is applied to process the sequencing data. Raw sequencing reads are assessed using QC tools to ensure data integrity and to identify any potential issues such as low-quality reads or adapter contamination. Subsequently, the reads are aligned to the GRCh37/hg19 genome assembly using STAR, allowing the accurate determination of splicing events. Quality criteria are applied for acceptance or rejection of the sequencing data. Accepted data is analyzed and used as additional evidence to evaluate the impact of the variant on splicing.

ANALYSIS STATISTICS

CentoGenome® MOx 2.0 Solo

Targeted nucleotides covered	≥ 10x	99.78%
------------------------------	-------	--------

LIMITATIONS

The genetic results are interpreted in the context of the provided clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the provided patient information or genetic data is inaccurate or incomplete. If the obtained genetic results are not compatible with the clinical findings, additional testing should be considered.

CentoGenome® MOx 2.0 Solo

Only variants in genes potentially related to the proband's provided clinical information are reported. Genes with mapping issues in the genome assembly used, and genomic regions that are hard to sequence by current technology and are without evidenced relevance for monogenic disorders, are excluded from this analysis. More complex genetic events not mentioned in the methods section, such as inversions and translocations, are not analyzed in this test. In addition, due to technology limitations, certain regions may be poorly covered, or not covered at all. In these regions and others encompassing repetitive, high-homology (such as pseudogene homology), and GC-rich sequences, relevant variants can be missed. Extremely low-coverage calls are expected to be artifacts based on our extensive validations and are consequently not considered during the analysis. Potential aberrant splicing is assessed with splice prediction tools. Deep intronic variants without strong prediction of aberrant splicing may not be reported, with the exception of known pathogenic splicing variants evidenced by external sources. The CNV detection sensitivity is decreased for repetitive regions, homologous regions such as pseudogenes, and for events spanning 2 or less exons. Due to methodological limitations, the sensitivity for detecting mosaic copy number variants (CNVs) is reduced. Furthermore, in cases where mosaic CNVs are detected, high allelic fractions may not be correctly recognized as mosaic. Mitochondrial variants with heteroplasmy levels below 15% may not be detected. It is expected that lower quality samples (e.g. prenatal, product of conception, blood from patients with hematologic disorders, and highly degraded DNA) may generate lower quality NGS data; in these cases, CNV analysis, mitochondrial genome analysis, and/or additional integrated screening analyses in this test may not be possible to perform. The repeat expansion algorithm used is not designed to handle complex loci that harbor multiple repeats. Repeats are only genotyped if the coverage at the locus is at least 10x. The Gaussian algorithm can only detect non-recombinant-like variants from a set of 111 known *GBA1* variants and can detect recombination events affecting exons 9-11 only. Therefore, recombinations affecting other regions are not in the scope of this screening. Silent carriers may be missed with the SMN Caller algorithm. The isoUPD detection is a screening method, and therefore false-positive and false-negative results may occur.

The quality of the RNA sequencing data may be significantly impaired by improper sample handling or sample preparation. This could be caused when the instructions for use are not followed (for example, using non-EDTA blood or non-freshly drawn blood for CentoCard® preparation, or extended shipping times). Samples received are extracted and processed only when 7 days or less have passed since blood collection. RNA integrity is evaluated after extraction, and only samples with RIN above 2.5 are processed. In each blood sample the expression of genes is subject to natural variation, leading to varying coverage information per gene. Consequently, genes with low expression in a sample cannot be analyzed if coverage data is not sufficient to evaluate splicing impact. Mapping tools rely on a reference genome, and any discrepancies between the reference and the sample's genome, such as genetic variation or novel transcripts, can result in alignment inaccuracies and potential loss of information (reference genome bias). The presence of highly similar or repetitive regions in the genome can lead to mapping ambiguities.

ADDITIONAL INFORMATION

This test was developed and validated by CENTOGENE. It is intended for clinical purposes. All test results are reviewed, interpreted, and reported by our scientific and medical experts.

To exclude mistaken identity in sample collection, several guidelines recommend testing a second sample independently obtained from the consultand.

As variant classification can change over time, please feel free to contact CENTOGENE in the future to inquire about classification changes of reported variants.

> Contact Details

Tel.: +49 (0)381 80113 416
Fax: +49 (0)381 80113 401
customer.support@centogene.com
www.centogene.com

CLIA registration 99D2049715; CAP registration 8005167. Scientific use of these results requires permission of CENTOGENE. If you would like to download your reports from our web portal, please contact us to receive your login and password. More information is available at www.centogene.com or customer.support@centogene.com.





DISCLAIMER

The preparation and processing of patient samples provided to CENTOGENE by a physician, clinical institution, or laboratory (by a "Partner"), as well as the genetic and/or biochemical testing requested, are performed according to the highest and most current scientific and analytical standards. However, in rare cases, genetic or biochemical tests may yield incorrect results—for example, due to the quality of the sample provided by the Partner, or due to unforeseeable or unknown factors beyond CENTOGENE's control. In such cases, CENTOGENE shall not be held responsible or liable for incomplete, potentially misleading, or incorrect results if the issue could not have been identified in advance.

COPYRIGHT NOTICE

This document contains information from the Online Mendelian Inheritance in Man® (OMIM®) database, used under license from Johns Hopkins University. This document does not represent the entire, unmodified OMIM® database, which is available at <http://omim.org/downloads>. OMIM® content: Copyright © 1996 – 2017, John Hopkins University, all rights reserved.

Chief Medical and Genomic Officer
Human Geneticist

Human Geneticist

Clinical Scientist
European Clinical Laboratory Geneticist
(ErCLG)

LABEL-272_V1.0_March 2026

> Contact Details

Tel.: +49 (0)381 80113 416
Fax: +49 (0)381 80113 401
customer.support@centogene.com
www.centogene.com

CLIA registration 99D2049715; CAP registration 8005167. Scientific use of these results requires permission of CENTOGENE. If you would like to download your reports from our web portal, please contact us to receive your login and password. More information is available at www.centogene.com or customer.support@centogene.com.

